Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) – Analysts at Leerink Swann issued their FY2020 earnings per share (EPS) estimates for shares of Paratek Pharmaceuticals in a research report issued on Monday, April 16th. Leerink Swann analyst A. Fadia forecasts that the specialty pharmaceutical company will post earnings of ($1.92) per share for the year. Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Paratek Pharmaceuticals’ FY2021 earnings at ($0.47) EPS and FY2022 earnings at $2.31 EPS.

How to Become a New Pot Stock Millionaire

Other equities analysts also recently issued research reports about the company. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Friday, February 16th. Cantor Fitzgerald set a $50.00 price objective on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, HC Wainwright upped their price objective on Paratek Pharmaceuticals from $43.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Paratek Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $40.00.

Shares of Paratek Pharmaceuticals stock opened at $13.35 on Tuesday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.72. Paratek Pharmaceuticals has a 52 week low of $11.85 and a 52 week high of $29.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.03). The business had revenue of $5.07 million during the quarter, compared to the consensus estimate of $5.00 million. Paratek Pharmaceuticals had a negative net margin of 706.00% and a negative return on equity of 93.16%.

Several hedge funds have recently modified their holdings of the business. Allianz Asset Management GmbH lifted its holdings in shares of Paratek Pharmaceuticals by 6.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 65,366 shares of the specialty pharmaceutical company’s stock worth $1,641,000 after buying an additional 3,719 shares during the period. Great West Life Assurance Co. Can purchased a new stake in shares of Paratek Pharmaceuticals during the 3rd quarter worth $104,000. SG Americas Securities LLC purchased a new stake in shares of Paratek Pharmaceuticals during the 3rd quarter worth $123,000. LPL Financial LLC lifted its stake in shares of Paratek Pharmaceuticals by 13.0% during the 4th quarter. LPL Financial LLC now owns 44,575 shares of the specialty pharmaceutical company’s stock worth $798,000 after purchasing an additional 5,125 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Paratek Pharmaceuticals by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 200,782 shares of the specialty pharmaceutical company’s stock worth $3,593,000 after purchasing an additional 5,151 shares during the last quarter. Institutional investors and hedge funds own 74.44% of the company’s stock.

In other Paratek Pharmaceuticals news, VP Adam Woodrow sold 14,333 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $13.87, for a total value of $198,798.71. Following the completion of the sale, the vice president now directly owns 62,367 shares in the company, valued at approximately $865,030.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert S. Radie sold 3,000 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $14.22, for a total value of $42,660.00. Following the completion of the sale, the director now owns 9,330 shares of the company’s stock, valued at $132,672.60. The disclosure for this sale can be found here. Insiders sold a total of 68,385 shares of company stock valued at $925,282 over the last quarter. Company insiders own 4.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Analysts Offer Predictions for Paratek Pharmaceuticals, Inc.’s FY2020 Earnings (PRTK)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/04/17/analysts-offer-predictions-for-paratek-pharmaceuticals-inc-s-fy2020-earnings-prtk.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.